{"id":874,"date":"2024-09-13T13:41:10","date_gmt":"2024-09-13T04:41:10","guid":{"rendered":"https:\/\/gucvmed.med.gunma-u.ac.jp\/?page_id=874"},"modified":"2024-09-13T13:44:06","modified_gmt":"2024-09-13T04:44:06","slug":"2023%e5%b9%b4%e6%a5%ad%e7%b8%be","status":"publish","type":"page","link":"https:\/\/gucvmed.med.gunma-u.ac.jp\/?page_id=874","title":{"rendered":"2023\u5e74\u5b66\u4f1a\u767a\u8868"},"content":{"rendered":"
\n

\u7b2c35<\/span>\u56de\u81e8\u5e8a\u4e0d\u6574\u8108\u7814\u7a76\u4f1a\u30002023.1.7<\/span>\uff08\u6771\u4eac\uff09<\/h4>\n

\u3010\u512a\u79c0\u6f14\u984c\u8cde\u3011\u5c0f\u91dd\u5c2d\u53f8\u3001\u91d1\u53e4\u5584\u660e\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u9577\u8c37\u5ddd\u3000\u5bdb\u3001\u77f3\u4e95\u79c0\u6a39\uff0e<\/p>\n

\u4e2d\u4f4d\u51a0\u9759\u8108\u6d1e\u3042\u308b\u3044\u306f\u30d2\u30b9\u675f\u3092\u5fc3\u623f\u6700\u65e9\u671f\u3068\u3059\u308bfast-slow AVNRT\u306e\u4e00\u4f8b\uff0e<\/p>\n

\u7b2c3<\/span>\u56de\u65e5\u672c\u4e0d\u6574\u8108\u5fc3\u96fb\u5b66\u4f1a\u95a2\u6771\u7532\u4fe1\u8d8a\u5730\u65b9\u4f1a\u30002023.1.28\uff08\u7532\u5e9c<\/span>\uff09<\/h4>\n

\u9577\u8c37\u5ddd\u3000\u5bdb\u3001\u91d1\u53e4\u5584\u660e\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u5c0f\u91dd\u5c2d\u53f8\u3001\u77f3\u4e95\u79c0\u6a39\uff0e<\/p>\n

\u5bc6\u5ea6\u30de\u30c3\u30d4\u30f3\u30b0\u304c\u7de9\u5f90\u4f1d\u5c0e\u8def\u90e8\u4f4d\u5185\u306e\u96fb\u4f4d\u306e\u691c\u51fa\u306b\u6709\u7528\u3067\u3042\u3063\u305f\u30d5\u30a1\u30ed\u30fc\u00a0\u56db\u5fb4\u75c7\u8853\u5f8c\u5fc3\u623f\u983b\u62cd\u306e\u4e00\u4f8b\uff0e<\/p>\n

\u7b2c267\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u95a2\u6771\u7532\u4fe1\u8d8a\u5730\u65b9\u4f1a\u30002023.2.25\uff08<\/span>\u6771\u4eac\uff09<\/h4>\n

\uff11\uff09\u53cd\u753a\u79c0\u7f8e
\n<\/span>\u7b2c14<\/span>\u56de\u30c0\u30a4\u30d0\u30fc\u30b7\u30c6\u30a3\u30fb\u30d5\u30a9\u30fc\u30e9\u30e0\u30fb\u7b2c3<\/span>\u56de\u3000U<\/span>\uff0d40<\/span>\u4f01\u753b\u30bb\u30c3\u30b7\u30e7\u30f3\u300c\u82e5\u624b\u5faa\u74b0\u5668\u533b\u306e5<\/span>\u3064\u306e\u30b9\u30c8\u30fc\u30ea\u30fc\uff5e\u82e5\u624b\u3068\u3057\u3066\u3001\u305d\u3057\u3066\u5148\u8f29\u3068\u3057\u3066\uff5e\u300d<\/p>\n

\uff12\uff09\u6e6f\u6d45\u76f4\u7d00\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u539f\u7530\u667a\u6210\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u5c0f\u4fdd\u65b9\u3000\u512a\u3001\u52a0\u85e4\u5bff\u5149\u3001\u77f3\u4e95\u79c0\u6a39
\n<\/span>\u598a\u5a20\u521d\u671f\u306b\u5fc3\u6a5f\u80fd\u4f4e\u4e0b\u3092\u304d\u305f\u3057\u305f\u3001\u7dad\u6301\u900f\u6790\u60a3\u8005\u306e\u4e00\u4f8b<\/p>\n

\uff13\uff09\u5c0f\u8c37\u91ce\u62d3\u4e5f\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u6e6f\u6d45\u76f4\u7d00\u3001\u539f\u7530\u667a\u6210\u3001\u5c0f\u4fdd\u65b9\u512a\u3001\u52a0\u85e4\u5bff\u5149\u3001\u9ad8\u9593\u5178\u660e\u3001\u77f3\u4e95\u79c0\u6a39
\n<\/span>\u904b\u52d5\u8ca0\u8377\u53f3\u5fc3\u30ab\u30c6\u30fc\u30c6\u30eb\u691c\u67fb\u306b\u3088\u308a\u7570\u306a\u308b\u606f\u5207\u308c\u306e\u539f\u56e0\u304c\u660e\u3089\u304b\u306b\u306a\u3063\u305f\u5f37\u76ae\u75c7\u306e\u4e8c\u4f8b<\/p>\n

\uff14\uff09\u5b89\u9054\u3000\u4ec1
\n<\/span>\u7fa4\u99ac\u770c\u306b\u304a\u3051\u308b\u5fc3\u4e0d\u5168\u5730\u57df\u9023\u643a\u306e\u53d6\u308a\u7d44\u307f<\/p>\n

\uff15\uff09\u4e45\u91ce\u8cb4\u5f18\u3001\u6edd\u6ca2\u5927\u6a39\u3001\u4f50\u91ce\u5e78\u6075\u3001\u5929\u5185\u58eb\u90ce\u3001\u77f3\u6a4b\u6d0b\u5e73\u3001\u9ad8\u9593\u5178\u660e\u3001\u77f3\u4e95\u79c0\u6a39
\n<\/span>\u6025\u6fc0\u306a\u7d4c\u904e\u3092\u8fbf\u308a\u3001\u51fa\u8840\u6027\u5408\u4f75\u75c7\u306e\u305f\u3081\u6551\u547d\u3057\u5f97\u306a\u304b\u3063\u305f\u5287\u75c7\u578b\u30ea\u30f3\u30d1\u7403\u6027\u5fc3\u7b4b\u708e\u306e\uff11\u4f8b<\/p>\n

\uff16\uff09\u7bc1\u3000\u60a0\u592a\u3001\u91d1\u5b50\u667a\u6d0b\u3001\u5802\u5782\u5927\u5fd7\u3001\u7802\u5c71\u3000\u52c9\u3001\u4e2d\u51fa\u3917\u8f14\u3001\u6817\u7530\u3000\u6893\u3001\u9060\u85e4\u88d5\u4e45\u3001\u9375\u5c71\u66a2\u4e4b\u3001\u9ed2\u7530\u4fca\u4ecb\u3001\u672b\u6c38\u88d5\u54c9\u3001\u6e05\u6c34\u9038\u5e73\u3001\u5357\u91ce\u3000\u5fb9\u3001\u5c0f\u4fdd\u65b9\u3000\u512a<\/p>\n

\u4fb5\u8972\u7684\u5fc3\u80ba\u904b\u52d5\u8ca0\u8377\u8a66\u9a13\u306b\u3088\u308a\u8a3a\u65ad\u306b\u81f3\u3063\u305f\u99c6\u51fa\u7387\u306e\u4fdd\u305f\u308c\u305f\u5fc3\u4e0d\u5168\u306e\u4e00\u4f8b<\/p>\n

ACC.23\u30002023.3.4-6\u3000\uff08New Orleans\uff09<\/span><\/h4>\n

1)Kodama C,Takama N,Ishii H<\/p>\n

Bleeding event in acute period is major poor prognosis factor for patients with<\/p>\n

pulmonary arterial hypertension initiating epoprostenol treatment<\/p>\n

2)Kodama C,Takama N,Ishii H.<\/p>\n

Relationships between endocrine diseases and high-dose epoprostenol therapy for patients<\/p>\n

with pulmonary arterial hypertension<\/p>\n

\uff0e<\/span><\/p>\n

\u7b2c87\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30002023.3.10-12<\/span>\u3000\uff08\u798f\u5ca1\uff09<\/h4>\n

1\uff09\u77f3\u4e95\u79c0\u6a39<\/p>\n

\u65e5\u672c\u5faa\u74b0\u5668\u9023\u5408up-to-date<\/span>\u300c\u65e5\u672c\u5fc3\u8840\u7ba1\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\u6cbb\u7642\u5b66\u4f1a\u300dCOVID-19<\/span>\u30d1\u30f3\u30c7\u30df\u30c3\u30af\u798d\u306b\u304a\u3051\u308b\u51a0\u52d5\u8108\u8840\u884c\u518d\u5efa\u6cbb\u7642<\/p>\n

COVID-19\u30a2\u30f3\u30b1\u30fc\u30c8\u8abf\u67fb\u304b\u3089\u898b\u3048\u308b\u3082\u306e<\/p>\n

2\uff09\u68ee\u3000\u60a6\u5b50\u3001\u77f3\u4e95\u79c0\u6a39\u3001\u677e\u6d66\u5e83\u6634\u3001\u5fd7\u6c34\u91cc\u7dd2\u3001\u4f50\u85e4\u7dbe\u5b50\u3001\u6fa4\u7530\u96c4\u77e2\u3001\u4e09\u7530\u7f8e\u6c99\u6a39\u3001\u77f3\u6a4b\u3000\u6e09\u3001\u6cb3\u91ce\u88d5\u6cbb\u3001\u5e73\u585a\u667a\u5eb7\u3001\u9752\u67f3\u967d\u4e00\u90ce\u3001\u7956\u7236\u6c5f\u5609\u6d0b\u3001\u6e21\u9089\u82f1\u4e00\u3001\u52a0\u8cc0\u8c37\u3000\u6589<\/p>\n

\u30c1\u30fc\u30e0\u533b\u7642\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u30a6\u30a3\u30ba\u30b3\u30ed\u30ca\u30fb\u30dd\u30b9\u30c8\u30b3\u30ed\u30ca\u6642\u4ee3\u306e\u5fc3\u81d3\uff98\uff8a\uff8b\uff9e\uff98\uff83\uff70\uff7c\uff6e\uff9d<\/p>\n

COVID-19\u6d41\u884c\u4e2d\u30ea\u30cf\u30d3\u30ea\u30bb\u30f3\u30bf\u30fc\u4f7f\u7528\u5236\u9650\u304c\u3042\u308b\u4e2d\u3067\u306e\u7c21\u6613\u578b\u30a8\u30eb\u30b4\u30e1\u30fc\u30bf\u306e\u5c0e\u5165\u3068\u751f\u6d3b\u69d8\u5f0f\u306b\u3064\u3044\u3066\u306e\u8abf\u67fb<\/p>\n

\uff13)\u5ca9\u4e95\u9f8d\u592a\u90ce\u3001\u9ad8\u9593\u5178\u660e\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

Controlled Heart Rate at Discharge Reduced LVEF Reduction and Heart Failure Rehospitalization after CABG Surgery<\/p>\n

4)Takizawa D,Harada T,Yuasa N,Sorimachi H,Kato T,Obokata M,Ishii H.<\/span><\/p>\n

Prognostic Value of Cardiac Power Output Reserve in Patients with Heart Failure and Preserved Ejection Fraction<\/p>\n

5)Kaneko Y,Fukuda K,Irie T,Shimizu H,Tamura S,Kobari T,Hasegawa H,Ishii H.<\/p>\n

Electrophysiological characteristics and catheter ablation of atypical fast-slow atrioventricular nodal reentrant tachycardia using an inferolateral left atrial slow pathway<\/p>\n

6) Sorimachi H,Yuasa N,Harada T,Kato T,Obokata M,Ishii H.<\/p>\n

Distinct Impact of Lung Diffusing Capacity on Cardiac Functions and Exercise Capacity in Heart Failure with Preserved Ejection Fraction<\/p>\n

7\uff09Yuasa N,Obokata M,Harada T,Kagami K,Sorimachi H,Saito Y,Kato T,Ishii H.<\/span><\/p>\n

Pathophysiologic and Prognostic Impact of Chronotropic Incompetence in Heart Failure with Preserved Ejection Fraction<\/p>\n

8\uff09\u5c0f\u677f\u6a4b\u7d00\u901a<\/p>\n

HFrEF\u306e\u57fa\u790e\u306e\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0<\/p>\n

9\uff09\u4e45\u91ce\u8cb4\u5f18<\/p>\n

COMMAND-VTE2\u306e\u6f14\u984c<\/p>\n

10\uff09\u5c0f\u677f\u6a4b\u7d00\u901a<\/p>\n

\u9662\u5185\u80ba\u585e\u6813\u4e88\u9632\u306eQI <\/span><\/p>\n

11\uff09\u5c0f\u677f\u6a4b\u7d00\u901a<\/p>\n

\u598a\u5a66\u306b\u5bfe\u3059\u308b\u30d8\u30d1\u30ea\u30f3\u306e\u4f7f\u7528\u306e\u30ec\u30c8\u30ed\u306e\u89e3\u6790<\/p>\n

12\uff09\u4f50\u91ce\u5e78\u6075<\/p>\n

HIV\u5fc3\u7b4b\u75c7\u306e\u75c7\u4f8b\u5831\u544a<\/p>\n

13)Sano Y,Koitabashi N,Tomono J,Ishii H.<\/p>\n

A case of Human Immunodeficiency Virus-associated Cardiomyopathy with Left Ventricular Thrombus,Successfully Treated with Medical Therpy and Cardiac Rehavilitation<\/p>\n

14\uff09\u5929\u5185\u58eb\u90ce\u3001\u9ad8\u9593\u5178\u660e\u3001\u690e\u540d\u8cb4\u884c\u3001\u85e4\u4e95\u5b5d\u6210\u3001\u77f3\u6a4b\u6d0b\u5e73\u3001\u52a0\u85e4\u5bff\u5149\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

Real-World Data in the Management of Hypertension for Patients with Sleep Disordered Breathing After Initiating Continuous Positive Airway Pressure Treatment<\/p>\n

15\uff09\u4e0a\u7fbd\u3000\u5353\u3001\u5929\u5185\u58eb\u90ce\u3001\u5150\u7389\u667a\u83ef\u3001\u6edd\u6ca2\u5927\u6a39\u3001\u77f3\u6a4b\u6d0b\u5e73\u3001\u85cd\u539f\u548c\u53f2\u3001\u9ad8\u9593\u5178\u660e\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u91d1\u53e4\u5584\u660e\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

Out-of-hospital Cardiac Arrest with Severe Electrolyte Abnormality and Hypoalbuminemia due to Strict Vegan Diet: An Unusual Presentation<\/p>\n

16\uff09Nakajima T,Tamura S,Hasegawa H,Kobari T,Ikeda K,Niwamae N,Tange S,Kurabayashi M,Kaneko Y,Ishii H<\/p>\n

Clinical and Electrocardiographic Features that Lead to a Diagnosis with Epilepsy in Genetically-Diagnosed LQTS Patients<\/p>\n

17\uff09Kaneko Y,Fukuda K,Irie T,Shimizu H,Tamura S,Kobari T,Hasegawa H, Ishii H.<\/p>\n

Electrophysiological characteristics and catheter ablation of atypical fast-slow atrioventricular nodal reentrant tachycardia using an inferolateral left atrial slow pathway.<\/p>\n

18\uff09Sunaga H,Matsui H,Yogi Umbarawan,Furukawa N,Kawakami R,Iso T,Koitabashi N,Matsuzaka T,Shimano H,Yokoyama T,Ishii H,Kurabayashi M.<\/span><\/p>\n

Genetic deletion of Elovl6 in cardiac fibroblast attenuates fibrotic response during pressure overload in mice.<\/p>\n

19)\u5c0f\u4fdd\u65b9\u512a<\/p>\n

Cardiac Power Output is Independently and Incrementally Associated with Adverse Outcomes in Heart Failure with Preserved Ejection Fraction<\/p>\n

:Circulation Cardiovascular Imaging.2022;15:e013495<\/p>\n

20\uff09Nagata R,Obokata M,Matsui H,Sunaga H,Kawakami R,Harada T,Iso T,Yokoyama T,Ishii H.<\/span><\/p>\n

Inflammatory cytokine production by visceral fat in heart failure with preserved ejection fraction<\/p>\n

21)Tanabe R,Matsui H,Kawakami R,Yokoyama T,Kurabayashi M,Ishii H,Iso T.<\/p>\n

Comparison between urinary fatty acid binding protein 1 and neutrophil gelatinase-associated lipocalin in acetaminophen-induced acute kidney injury in mice<\/p>\n

22)Satoh Y,Matsui H,Sunaga H,Kawakami R,Iso T,Ishii H,Yokoyama T,Kurabayashi M.<\/p>\n

Deletion of fatty acid synthase in vascular smooth muscle cells attenuates neointima formation after vascular injury in mice.<\/p>\n

23\uff09\u5ead\u524d\u91ce\u83ca<\/p>\n

Effects of Cardiac Sympathetic Denervation for Refractory Vasospastic Angina and Electrical Ventricular Tachycardia Storm<\/p>\n

24\uff09\u5ead\u524d\u91ce\u83ca<\/p>\n

\u6551\u6025\u5553\u767a\u90e8\u4f1a\u3000\u4f01\u753b\u30bb\u30c3\u30b7\u30e7\u30f3<\/p>\n

AED\u666e\u53ca\u5553\u767a\u306e\u53d6\u308a\u7d44\u307f\uff5eAED GO<\/span>\u3001\u6551\u547d\u30b5\u30dd\u30fc\u30bf\u30fc\u30d7\u30ed\u30b8\u30a7\u30af\u30c8\uff5e<\/p>\n

25)Ishii H,Kohsaka S,Yamaji K,Sawano M,Amano T,Nakamura M,Ikari Y.<\/p>\n

COVID-19 Pandemic and Performance of PCI in Japan:National Survey Reports from CVIT Members and Structured Analysis of J-PCI Registry<\/p>\n

26)Koitabashi N,Torikai K,Takizawa M,Ohyama Y,Saitoh Y,Komatsu Y,Ishii H.<\/p>\n

Effects of the Quality Improvement Project to Prevent in-hospital Venous Thromboembolism on Cancer-Related Thrombosis.<\/p>\n

27)Koitabashi N,Kameda T,Iwase A,Ishii H.<\/p>\n

A Retrospective Study of the Prognosis of Pregnant Women Treated with Subcutaneous Unfractionated Heparin<\/p>\n

28)Kuno<\/span>\u3000T,Koitabashi N,Ohyama Y,Takama N,Obokata M,Chatani R,Kaneda K,Nishimoto Y,Ikeda N,Kobayashi T,Ikeda S,Kitae Kim,Takase T,Tsuji S,Ohi M,Takada T Otsui K,Sakamoto J,Yamashita Y,Ishii H.<\/span><\/p>\n

Actual Management of Venous Thromboembolism by Antiphospholipid Antibody Syndrome in Japan.From the COMMAND VTE Registry-2<\/p>\n

Actual Management of Venous Thromboembolism Complicated by Antiphospholipid Antibody Syndrome in Japan.From the COMMAND VTE Registry-2<\/p>\n

29) \u5916\u5c71\u5353\u4e8c\u3001\u7b20\u9593\u3000\u9031\u3001\u4f50\u85e4\u4e07\u57fa\u4eba\u3001\u4e2d\u539f\u5065\u88d5\u3001\u4f50\u91ce\u5b8f\u548c\u3001\u690d\u7530\u54f2\u4e5f\u3001\u4f50\u3005\u6728\u8c4a\u5fd7\u3001\u5009\u6797\u6b63\u5f66\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

The Differences of Prognostic-Factors between Mild(30\u2264eGFR<\/span>\uff1c60)and Severe(eGFR<30)Chronic-Kidney-Disease Patients for Major-Adverse-Cardiac-Cerebrovascular-Renal-Events for 5 Years:Sub-Analysis of the Gunma CKD SPECT Multi-Center-Study<\/span><\/p>\n

30)Koitabashi N,Furukawa N,Matsui H,Obinata H,Yokoyama T,Kurabayashi M,Ishii H.<\/p>\n

Sacubitril\/Valsartan Increases Titin Phosphorylation and Improves Passive Myocardial Stiffness in Diabetic Mice<\/p>\n

31)Fujii T,Takama N,Iwai R,Kodama C,Takizawa D,Amanai S,Koitabashi N,Kaneko Y,Ishii H<\/p>\n

Heart Failure with Recovered Ejection Fraction is Good Therapeutic Merkmal for Adaptive-Servo Ventilation Therapy in Patients with Heart Failure<\/p>\n

32)\u85e4\u4e95\u5b5d\u6210\u3001\u9ad8\u9593\u5178\u660e\u3001\u5150\u7389\u667a\u83ef\u3001\u5c0f\u677f\u6a4b\u7d00\u901a\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

Relationships between Endocrine Diseases and High-dose Epoprostenol Therapy for Patients with Pulmonary Arterial Hypertension<\/p>\n

33)Furukawa N,Kondo N,Miyazaki A,Ozeki K,Koitabashi N,Nagata K,Ishikawa T,Ohno K,Hirayama M.<\/p>\n

Soy Protein Be-ta-Conglycinin Has Potential as a Novel Previotics for Heart Failure via the Gut-Heart Linkage<\/p>\n

34)Saito Y,Inohara T,Kohsaka S,Andoh H,Ishii H,Yamaji K,Amano T,Kobayashi Y,Kohzuma K<\/p>\n

Volume-Outcom Relationships of Percutaneous Coronary Intervention in Patients Presenting with Acute Myocardial Infarction :Insights from the J-PCI Registry<\/p>\n

35)Koitabashi N,Trikai K,Takizawa M,Ohyama Y,Saito Y,Komatsu Y,Ishii H.<\/p>\n

Effects of the Qualty Improvement Project to Prevent in-hospital Venous Thromboembolism on Cancer-Related Thrombosis.<\/p>\n

36)Kunieda T,Tanaka A,Shirai Y,Kurobe M,Tokuda K,Tobe A,Mizutani K,Miyazaki T,Kubota Y,Furusawa K,Ishii H,Murohara T<\/p>\n

Incidence of Cardiac Events Following Non-cardiac Surgery among the Patients with or without Coronary Artery Stenosis by Pre-operative Coronary Angiography<\/p>\n

37)Ozaki Y,Kawai H,Muramatsu T,Watarai M,Ajioka M,Shimizu K,Oguri M,Kondoh T,Morishima I,Harada K,Suwa S,Oka T,Kamiya H,Matsuo H,Harada M,Maekawa Y,Ishii H,Amano T,Izawa H,Murohara T<\/p>\n

Five-year Prospective Rivaroxaban and Warfarin Therapy in Real-World Patients with Coronary Stents,Atrial Fibrillation,and\u00a0 Chronic Kidney,Disease(CKD)<\/p>\n

38)\u5fb3\u7530\u6643\u592a\u90ce\u3001\u7530\u4e2d\u54f2\u4eba\u3001\u767d\u4e95\u7fa9\u61b2\u3001\u9ed2\u90e8\u5c06\u6210\u3001\u6238\u90e8\u5f70\u6d0b\u3001\u4e45\u4fdd\u7530\u559c\u79cb\u3001\u570b\u679d\u6b66\u8302\u3001\u53e4\u6fa4\u5065\u53f8\u3001\u77f3\u4e95\u79c0\u6a39\u3001\u5ba4\u539f\u8c4a\u660e<\/p>\n

Impact of C-reactive Protein on Long-term Cardiac Events in Stable Coronary,Artery Disease Patients with Chronig Kidney Disease<\/p>\n

39)Nakatani Y, Take Y, Takizawa R, Goto K, Kaseno K, Yoshimura S, Haraguchi Y, Aoki H, Ishikawa R, Kimura K, Sasaki T, Miki Y, Nakamura K, Naito S. Catheter ablation approach targeting epicardial connection to the right pulmonary vein antrum detected before pulmonary vein isolation.<\/p>\n

40)Nakatani Y, Take Y, Takizawa R, Kaseno K, Goto K, Yoshimura S, Haraguchi Y, Sasaki T, Miki Y, Aoki H, Ishikawa R, Kimura K, Nakamura K, Naito S. Differentiation of atrial tachycardia from supraventricular tachycardia by a paraHisian single extra-stimulation.<\/p>\n

41)\u85e4\u7530\u3000\u51db\u3001\u5c0f\u6817\u5149\u4fca\u3001\u5c0f\u5cf6\u6167\u58eb\u3001\u7e04\u91ce\u53cb\u660e\u3001\u91cd\u677e\u62d3\u6717\u3001\u5c0f\u5c71\u96c4\u4e00\u90ce\u3001\u7247\u6850\u3000\u5065\u3001\u732a\u98fc\u4f73\u5f18\u3001\u85e4\u5ddd\u88d5\u4ecb\u3001\u77f3\u4e95\u79c0\u6a39\u3001\u5ba4\u539f\u8c4a\u660e<\/p>\n

The Impact of Clinical Frailty Scale on Prediction of Long-term Mortality in Hospitalized Acute Heart Failure Patients<\/p>\n

\u7b2c35<\/span>\u56de\u81e8\u5e8a\u4e0d\u6574\u8108\u7814\u7a76\u4f1a\u30002023.1.7<\/span>\uff08\u6771\u4eac\uff09<\/h4>\n

\u3010\u512a\u79c0\u6f14\u984c\u8cde\u3011\u5c0f\u91dd\u5c2d\u53f8\u3001\u91d1\u53e4\u5584\u660e\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u9577\u8c37\u5ddd\u3000\u5bdb\u3001\u77f3\u4e95\u79c0\u6a39\uff0e<\/p>\n

\u4e2d\u4f4d\u51a0\u9759\u8108\u6d1e\u3042\u308b\u3044\u306f\u30d2\u30b9\u675f\u3092\u5fc3\u623f\u6700\u65e9\u671f\u3068\u3059\u308bfast-slow AVNRT\u306e\u4e00\u4f8b\uff0e<\/p>\n

16th Congress of the European Cardiac Arrhythmia Society.\u00a0 2023.3.26 (Paris\uff09<\/h4>\n

Kaneko Y.<\/p>\n

Fast-slow AVNRT vs ATP sensitive AT.13th Japan HRS-ECAS<\/p>\n

\u65e5\u672c\u5fc3\u30a8\u30b3\u30fc\u56f3\u5b66\u4f1a\u7b2c34<\/span>\u56de\u5b66\u8853\u96c6\u4f1a\u30002023.4.21-22<\/span><\/h4>\n

1) \u5c0f\u4fdd\u65b9\u512a<\/p>\n

\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\u3000HFpEF\u306e\u65e9\u671f\u8a3a\u65ad\u30fb\u6cbb\u7642\u306eUp-to-date\u00a0\u301c\u904b\u52d5\u8ca0\u8377\u5fc3\u30a8\u30b3\u30fc\u56f3\u3092\u4f7f\u3063\u305f\u30a2\u30d7\u30ed\u30fc\u30c1\u301c<\/p>\n

2\uff09\u5c0f\u4fdd\u65b9\u512a<\/p>\n

EACVI-JSE Joint Symposium Cardio-oncology<\/p>\n

3\uff09\u5c0f\u4fdd\u65b9\u512a<\/p>\n

\u30b7\u30f3\u30dd\u30b8\u30a6\u30e01\u00a0\u5de6\u5ba4\u62e1\u5f35\u80fd\u8a3a\u65ad\u306e\u6700\u524d\u7dda\u3000\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u6539\u5b9a\u306f\u8fd1\u3044\u304b\uff1f<\/p>\n

4\uff09\u6e6f\u6d45\u76f4\u7d00<\/p>\n

10126 HFpEF\u3092\u5408\u4f75\u3057\u305f\u5f37\u76ae\u75c7\u60a3\u8005\u306e\u904b\u52d5\u8010\u5bb9\u80fd\u3001\u5fc3\u8840\u7ba1\u4e88\u5099\u80fd\u306e\u4f4e\u4e0b<\/p>\n

5\uff09\u77f3\u4e95\u667a\u6643\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u52a0\u85e4\u5bff\u5149\u3001\u539f\u7530\u667a\u6210\u3001\u6e6f\u6d45\u76f4\u7d00\u3001\u93e1\u548c\u6a39\u3001\u5185\u85e4\u6731\u7f8e\u3001\u9f4b\u85e4\u4f51\u8a18\u3001\u77f3\u4e95\u79c0\u6a39\u3001\u5c0f\u4fdd\u65b9\u512a<\/p>\n

HFpEF\u306b\u304a\u3051\u308b\u6700\u5927\u904b\u52d5\u8ca0\u8377\u6642\u306e\u4e2d\u9694\u306e\u53ce\u7e2e\u671f\u50e7\u5e3d\u5f01\u8f2a\u30c9\u30d7\u30e9\u901f\u5ea6\uff08\uff53\u2018<\/span>\uff09\u3068\u4e88\u5f8c\u3068\u306e\u95a2\u9023<\/p>\n

6\uff09\u6751\u4e0a\u6587\u5d07\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5ead\u524d\u91ce\u83ca\u3001\u5cef\u5cb8\u7f8e\u667a\u5b50\u3001\u4f50\u3005\u6728\u5b5d\u5fd7\u3001\u661f\u91ce\u572d\u6cbb\u3001\u77f3\u5c3e\u6d35\u4e00\u90ce\u3001\u897f\u5c3e\u7406\u6c99\u3001\u4e39\u4e0b\u6b63\u4e00<\/p>\n

\u7d4c\u80f8\u58c1\u5fc3\u30a8\u30b3\u30fc\u56f3\u691c\u67fb\u3067\u518d\u767a\u4e73\u764c\u306e\u53f3\u623f\u8ee2\u79fb\u5de3\u3092\u89b3\u5bdf\u3057\u5f97\u305f\u4e00\u4f8b<\/p>\n

\u7b2c61<\/strong>\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\u6cbb\u7642\u5b66\u4f1a\u95a2\u6771\u7532\u4fe1\u8d8a\u5730\u65b9\u4f1a\u30002023.5.13<\/span>\uff08\u6771\u4eac\uff09<\/strong><\/h4>\n

\u4e0a\u7fbd \u5353\uff0c\u5929\u5185 \u58eb\u90ce\uff0c\u5150\u7389 \u667a\u83ef\uff0c\u6edd\u6ca2 \u5927\u6a39\uff0c\u4e45\u91ce \u8cb4\u5f18\uff0c\u77f3\u6a4b \u6d0b\u5e73\uff0c\u9ad8\u9593 \u5178\u660e\uff0c\u77f3\u4e95\u79c0\u6a39<\/p>\n

\u524d\u4e0b\u884c\u679d\u306b\u5bfe\u3057\u3066\u30b7\u30ed\u30ea\u30e0\u30b9\u6eb6\u51fa\u6027\u30b9\u30c6\u30f3\u30c8(SES)<\/span>\u3092\u7559\u7f6e\u5f8c\uff0c\u5f8c\u62e1\u5f35\u3067\u4e3b\u5e79\u90e8\u3078\u306e\u8457\u660e\u306a\u4f38\u9577\u3092\u8a8d\u3081\u305f ST <\/span>\u4e0a\u6607\u578b\u6025\u6027\u5fc3\u7b4b\u6897\u585e\u306e 1 <\/span>\u4f8b<\/p>\n

\u7b2c53\u56de\u81e8\u5e8a\u5fc3\u81d3\u96fb\u6c17\u751f\u7406\u7814\u7a76\u4f1a\u30002023.5.27\uff08\u6771\u4eac<\/span>\uff09<\/h4>\n

\u5c0f\u91dd\u5c2d\u53f8\u3001\u91d1\u53e4\u5584\u660e\u3001\u7530\u6751\u5cfb\u592a\u90de\u3001\u9577\u8c37\u5ddd\u5bdb\u3001\u77f3\u4e95\u79c0\u6a39\uff0e<\/p>\n

\u904e\u5e38\u4f1d\u5c0e\u3092\u5448\u3057\u305f\u5de6\u5074concealed nodoventricular fiber<\/span>\u3092\u4ecb\u3059\u308b\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u4e00\u4f8b\uff0e<\/p>\n

\u65e5\u672c\u8d85\u97f3\u6ce2\u533b\u5b66\u4f1a\u7b2c96<\/span>\u56de\u5b66\u8853\u96c6\u4f1a\u30002023.5.27-29<\/span>\uff08\u5927\u5bae\uff09<\/h4>\n

1\uff09\u5c0f\u4fdd\u65b9\u512a
\n<\/span>\u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3\u3000\u5de6\u623f\u306b\u95a2\u308f\u308b\u8af8\u554f\u984c\u3092\u5fc3\u30a8\u30b3\u30fc\u56f3\u3067\u8a3a\u308b
\n\u5de6\u5ba4\u99c6\u51fa\u7387\u306e\u4fdd\u305f\u308c\u305f\u5fc3\u4e0d\u5168\u306e\u65e9\u671f\u8a3a\u65ad\u306b\u5de6\u623f\u6a5f\u80fd\u8a55\u4fa1\u306f\u6709\u7528\u5316\uff1f
\n2<\/span>\uff09\u5742\u4e95\u4fca\u82f1\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5bae\u5d8b\u73b2\u4eba\u3001\u95a2\u53e3\u8aa0\u3001\u7530\u53e3\u54f2\u4e5f\u3001\u5e02\u5ddd\u5553\u4ecb\u3001\u91d1\u4e95\u674f\u5948\u3001\u9577\u8c37\u5ddd\u4fee\u4e00<\/p>\n

\u4eee\u6027\u7624\u3068\u763b\u5b54\u3092\u5408\u4f75\u3057\u305f\u5927\u52d5\u8108\u5f01\u4f4d\u4eba\u5de5\u5f01\u611f\u67d3\u6027\u5fc3\u5185\u819c\u708e\u306e1<\/span>\u4f8b<\/p>\n

3\uff09\u5c0f\u4fdd\u65b9\u512a<\/p>\n

\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\u5fc3\u30a8\u30b3\u30fc\u56f3\u3092\u4f7f\u3063\u305f\u606f\u5207\u308c\u60a3\u8005\u3078\u306e\u30a2\u30d7\u30ed\u30fc\u30c1<\/p>\n

4\uff09\u6751\u4e0a\u6587\u5d07\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5ead\u524d\u91ce\u83ca\u3001\u5cef\u5cb8\u7f8e\u667a\u5b50\u3001\u4f50\u3005\u6728\u5b5d\u5fd7\u3001\u661f\u91ce\u572d\u6cbb\u3001\u77f3\u5c3e\u6d35\u4e00\u90ce\u3001\u897f\u5c3e\u7406\u6c99\u3001\u4e39\u4e0b\u6b63\u4e00<\/p>\n

\u7d4c\u80f8\u58c1\u5fc3\u81d3\u8d85\u97f3\u6ce2\u691c\u67fb\u3067\u89b3\u5bdf\u3057\u5f97\u305f\u5fc3\u5c16\u90e8\u5fc3\u819c\u56a2\u80de\u3068\u5de6\u4e0a\u5927\u9759\u8108\u907a\u6b8b\u3092\u4f75\u5b58\u3057\u305f\u4e00\u4f8b<\/p>\n

\uff15\uff09\u4e95\u4e0a\u5948\u6d25\u5e0c\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5ca9\u702c\u771f\u5948\u7f8e\u3001\u6a2a\u5800\u5f25\u751f\u3001\u9ad8\u6728\u5bff\u60a6\u4ec1\u3001\u9808\u85e4\u660e\u5b50\u3001\u539f\u7530\u667a\u6210\u3001\u6708\u5ca1\u5927\u543e\u3001\u9db4\u8c37\u82f1\u6a39<\/p>\n

\u91cd\u75c7\u50e7\u5e3d\u5f01\u9589\u9396\u4e0d\u5168\u75c7\u3092\u4f34\u3046Marfan<\/span>\u75c7\u5019\u7fa4\u306e1<\/span>\u4f8b<\/p>\n

6\uff09\u6751\u4e0a\u6587\u5d07\u3001\u539f\u7530\u667a\u6210\u3001\u6e6f\u6d45\u76f4\u7d00\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u52a0\u85e4\u5bff\u5149\u3001\u77f3\u4e95\u79c0\u6a39\u3001\u5c0f\u4fdd\u65b9\u512a<\/p>\n

HFpEF<\/span>\u60a3\u8005\u306b\u304a\u3051\u308b\u904b\u52d5\u8ca0\u8377\u5fc3\u30a8\u30b3\u30fc\u6642\u306e\u8840\u5727\u4e0a\u6607\u306e\u4e88\u5f8c\u3078\u306e\u5f71\u97ff\u306e\u691c\u8a0e<\/p>\n

\u7b2c\uff18\u56de\u80ba\u5faa\u74b0\u80ba\u9ad8\u8840\u5727\u5b66\u4f1a\u30002023.6.4\uff08\u795e\u6238<\/span>\uff09<\/h4>\n

\u5150\u7389\u667a\u83ef<\/p>\n

\u30a8\u30dd\u30d7\u30ed\u30b9\u30c6\u30ce\u30fc\u30eb\u5c0e\u5165\u75c7\u4f8b\u306e \u4e88\u5f8c\u898f\u5b9a\u56e0\u5b50\u306b\u3064\u3044\u3066<\/p>\n

\u7b2c\uff16\uff18\u56de\u65e5\u672c\u900f\u6790\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\u30002023.6.16-18<\/span>\uff08\u795e\u6238\uff09<\/h4>\n

\u95a2\u6839\u82b3\u5cb3\uff0c\u77f3\u5c3e\u5178\u5b50\uff0c\u5800\u3000\u6176\u5178\uff0c\u798f\u7530\u601c\u96c4\uff0c\u52a0\u85e4\u3000\u821e\uff0c\u8fbb\u3000\u88d5\u4eae\uff0c\u524d\u91ce\u4f51\u592a\uff0c\u6fa4\u7530\u9054\u5b8f\uff0c\u9808\u85e4\u4f51\u592a\uff0c\u9752\u6728\u96c5\u5178\uff0c\u5927\u6d25\u3000\u6643\uff0c\u9f4b\u85e4\u667a\u7f8e\uff0c\u85e4\u585a\u96c4\u53f8\uff0c\u65b0\u4e95\u8aa0\u4e8c\uff0c\u4f50\u85e4\u9054\u4e5f\uff0c\u5ca9\u702c\u3000\u660e,<\/span>\u6e6f\u6d45\u76f4\u7d00\uff0c\u5c0f\u677f\u6a4b\u7d00\u901a\uff0c\u77f3\u4e95\u79c0\u6a39<\/p>\n

\u598a\u5a20\u7d4c\u904e\u4e2d\u306b\u6162\u6027\u5fc3\u4e0d\u5168\u306e\u6025\u6027\u5897\u60aa\u3092\u8a8d\u3081\u305f\u8840\u6db2\u900f\u6790\u60a3\u8005\u306e1<\/span>\u4f8b<\/p>\n

\u7b2c69<\/span>\u56de\u65e5\u672c\u4e0d\u6574\u8108\u5fc3\u96fb\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30002023.7.6-9<\/span>\uff08\u672d\u5e4c\uff09<\/h4>\n

1\uff09\u91d1\u53e4\u5584\u660e<\/p>\n

\u6559\u80b2\u8b1b\u6f14\uff14\uff1aEPS<\/span>\u306b\u5fc5\u8981\u306a\u57fa\u790e\u77e5\u8b58\uff08\u4e0a\u8cea\u983b\u62cd\u7de8\u3001\u5fc3\u5ba4\u983b\u62cd\u7de8\uff09<\/p>\n

2\uff09Nakatani Y, Take Y, Yoshimura S, Takizawa R, Goto K, Kaseno K, Aoki H, Kimura K, Haraguchi Y, Sasaki T, Miki Y, Nakamura K, Naito S<\/span><\/p>\n

The distribution of branches of the vein of Marshall is a predictor of low voltage areas induced by ethanol infusion into the vein of Marshall.<\/p>\n

CVIT2023\u30002023.8.4-6<\/span>\uff08\u798f\u5ca1\uff09<\/h4>\n

\uff11\uff09Aihara K,Tani M,Yoneda K<\/p>\n

Epidemiology of Acute Coronary Syndrome in Isolated Islands: A Retrospective Cohort Study in the Miyako Islands<\/p>\n

\uff12\uff09\u5929\u5185\u58eb\u90ce<\/p>\n

Out-of-hospital Cardiac Arrest with Anomalous Aortic Origin of The Right Coronary Artery: What Should We Do?<\/p>\n

\uff13\uff09\u4e45\u91ce\u8cb4\u5f18
\na case of repeated restenosis of a covered stent gap,observed by angioscopy and OCT<\/span><\/p>\n

ESC2023\u30002023.8.25-8.28<\/span>\uff08\u30aa\u30e9\u30f3\u30c0\uff09<\/h4>\n

Takama N,Ueba S,Isobe I,Sano Y,Amanai S,Kuno T,Ishibashi Y,Kato T,Ishii H.<\/p>\n

Estimation of antihypertensive effect after initiating continuous positive airway pressure treatment in Japanese patients with sleep disordered breathing<\/p>\n

\u7b2c269<\/span>\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u95a2\u6771\u7532\u4fe1\u8d8a\u5730\u65b9\u4f1a\u30002023.9.2<\/span>\uff08\u6771\u4eac\uff09<\/h4>\n

Clinical Research Award \u512a\u79c0\u8cde<\/p>\n

\u6e6f\u6d45\u76f4\u7d00\u3001\u5c0f\u4fdd\u65b9\u3000\u512a\u3001\u6751\u4e0a\u6587\u5d07\u3001\u53cd\u753a\u79c0\u7f8e\u3001\u52a0\u85e4\u5bff\u5149\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

\u6f5c\u5728\u7684\u306a\u5de6\u5ba4\u62e1\u5f35\u969c\u5bb3\u3092\u5408\u4f75\u3057\u305f\u5f37\u76ae\u75c7\u60a3\u8005\u306e\u81e8\u5e8a\u7684\u610f\u7fa9<\/p>\n

\u7b2c\uff17\uff11\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30002023.9.8-10<\/span>\uff08\u6771\u4eac\uff09<\/h4>\n

\uff11\uff09\u9ad8\u9593\u5178\u660e<\/p>\n

\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff15\u300c\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u7761\u7720\u969c\u5bb3\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\u300d<\/p>\n

\uff12\uff09\u4e2d\u91ce\u8003\u82f1<\/p>\n

\u30a8\u30dd\u30d7\u30ed\u30b9\u30c6\u30ce\u30fc\u30eb\u6301\u7d9a\u6cbb\u7642\u306b\u3088\u308a\u30ea\u30f3\u30d1\u7403\u6027\u4e0b\u5782\u4f53\u708e\u3092\u5448\u3057\u305fRNF213<\/span>\u907a\u4f1d\u5b50\u306e\u5909\u7570\u3092\u6709\u3059\u308b\u672b\u68a2\u578b\u80ba\u52d5\u8108\u72ed\u7a84\u75c7\u306e1<\/span>\u4f8b<\/p>\n

\uff12\uff09\u5c0f\u4fdd\u65b9\u3000\u512a<\/p>\n

\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff18\u300cHFpEF<\/span>\u306e\u8a3a\u65ad\u30fb\u6cbb\u7642 Up-to-date ~SGLT2<\/span>\u963b\u5bb3\u85ac\u3078\u306e\u671f\u5f85~<\/span>\u300d<\/p>\n

\uff13\uff09\u5c0f\u4fdd\u65b9\u3000\u512a<\/p>\n

\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff11\uff11\u300cHFpEF<\/span>\u306e\u6cbb\u7642\u6226\u7565\u300d\u904b\u52d5\u8ca0\u8377\u5fc3\u30a8\u30b3\u30fc\u3092\u4f7f\u3063\u305fHFpEF<\/span>\u306e\u7a4d\u6975\u7684\u6cbb\u7642\u6226\u7565\u00a0<\/span><\/p>\n

\uff14\uff09\u77f3\u4e95\u79c0\u6a39<\/p>\n

\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff115<\/span>\u300c\u5fc3\u75be\u60a3\u6cbb\u7642\u306b\u304a\u3051\u308b\u8102\u8cea\u7570\u5e38\u75c7\u306e\u6b8b\u4f59\u30ea\u30b9\u30af\u7ba1\u7406\u2015\u9ad8\u5ea6EPA<\/span>\u88fd\u5264\u306e\u6709\u7528\u6027\u3092\u8003\u3048\u308b\u30fc\u300d<\/p>\n

\u7b2c27\u56de\u65e5\u672c\u5fc3\u4e0d\u5168\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30002023.10.6-8<\/span>\uff08\u6a2a\u6d5c\uff09<\/h4>\n

\uff11\uff09\u5c0f\u4fdd\u65b9\u512a<\/p>\n

\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\u300cHFpEF<\/span>\u6cbb\u7642\u306e\u6700\u9069\u5316\u3000~<\/span>\u30ab\u30ea\u30a6\u30e0\u7ba1\u7406\u306e\u91cd\u8981\u6027~<\/span>\u300d<\/p>\n

\uff12\uff09\u5c0f\u4fdd\u65b9\u512a
\n<\/span>\u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3\uff12\u300cEF<\/span>\u306b\u95a2\u3059\u308b\u8b70\u8ad6\u300d<\/p>\n

    <\/ul>\n

    \u7b2c69<\/span>\u56de\u65e5\u672c\u4e0d\u6574\u8108\u5fc3\u96fb\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30002023.7.6-9<\/span>\uff08\u672d\u5e4c\uff09<\/h4>\n

    1\uff09\u91d1\u53e4\u5584\u660e<\/p>\n

    \u6559\u80b2\u8b1b\u6f14\uff14\uff1aEPS<\/span>\u306b\u5fc5\u8981\u306a\u57fa\u790e\u77e5\u8b58\uff08\u4e0a\u8cea\u983b\u62cd\u7de8\u3001\u5fc3\u5ba4\u983b\u62cd\u7de8\uff09<\/p>\n

    HFSA2023\u30002023.10.6-9\uff08\u30af\u30ea\u30fc\u30d6\u30e9\u30f3\u30c9\uff09<\/h4>\n

    Sorimachi H,Obokata M, Kazunori Omote , Massar Omar , Dejana Popovic, Yogesh N.V. Reddy MBBS, MSc , Sanjiv J. Shah , Barry A. Borlaug<\/p>\n

    Race Differences of Cardiac structure, Function and Mortality in Heart Failure Patients with Preserved Ejection Fraction<\/p>\n

    \u7b2c60<\/span>\u56de\u65e5\u672c\u81e8\u5e8a\u751f\u7406\u5b66\u4f1a\u7dcf\u4f1a2023.10.21-22<\/span>\uff08\u7fa4\u99ac\uff09<\/h4>\n

    1\uff09\u5c0f\u4fdd\u65b9\u512a<\/span><\/p>\n

    \u904b\u52d5\u8ca0\u8377\u5fc3\u30a8\u30b3\u30fc\u306e\u5b9f\u8df5<\/p>\n

    2\uff09\u5c0f\u4fdd\u65b9\u512a<\/p>\n

    HFpEF\u306e\u8a3a\u65ad\u30fb\u6cbb\u7642\u306eUp-to-date<\/span>\u3000\uff5eSGLT2<\/span>\u963b\u5bb3\u85ac\u3078\u306e\u671f\u5f85\uff5e<\/p>\n

    AHA2023\u30002023.11.11-13\uff08Philadelphia\uff09<\/h4>\n

    1\uff09Koitabashi N,Kawakami R,Tokuyama T,Razan E Ahed,Fuad G Torial,Anzai T,Nagao Y,Ishii H,Uosaki H.
    \nGene Therapy Improves Pathological Cardiac Remodeling in Human Hypertrophic Cardiomyopathy gene Variant Knock-In Mice<\/p>\n

    2\uff09Kuno T,Koitabashi N,Ohyama Y,Takama N,Chatani R,Kaneda K,Nishimoto Y,Ikeda N,Kobayashi Y,Yamashita Y,Ishii H<\/p>\n

    Actual Management of Venous Thromboembolism Complicated by Antiphospholipid Antibody Syndrome in Japan.From the Command VTE Registry-2<\/p>\n

    \u30ab\u30c6\u30fc\u30c6\u30eb\u30a2\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\u79cb\u5b63\u5927\u4f1a2023<\/span>\u516c\u958b\u7814\u7a76\u4f1a\u30002023.11.18<\/span>\uff08\u798f\u5ca1\uff09<\/h4>\n

    1\uff09\u5c0f\u91dd\u5c2d\u53f8\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u8c37\u6d0b\u4ecb\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u9577\u8c37\u5ddd\u5bdb\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

    \u5fc3\u5ba4\u523a\u6fc0\u306b\u3088\u308b\u30d2\u30b9\u675f\u306e\u65e9\u671f\u6355\u6349\u3092\u8a8d\u3081\u305fconcealed nodoventricular fiber (cNV)<\/span>\u3092bystander<\/span>\u3068\u3059\u308bslow-fast AVNRT<\/span>\u306e\u4e00\u4f8b\uff0e<\/p>\n

    2\uff09\u7530\u6751\u5cfb\u592a\u90ce\u3001\u4e2d\u8c37\u6d0b\u4ecb\u3001\u5c0f\u91dd\u5c2d\u53f8\u3001\u9577\u8c37\u5ddd\u5bdb\u3001\u77f3\u4e95\u79c0\u6a39<\/p>\n

    \u53f3\u5ba4\u6d41\u51fa\u8def\u30d1\u30c3\u30c1\u306e\u5fc3\u5916\u819c\u5074\u5fc3\u7b4b\u3092\u56de\u8def\u306b\u542b\u3080\u3068\u8003\u3048\u3089\u308c\u305f\u30d5\u30a1\u30ed\u30fc\u56db\u5fb4\u75c7\u8853\u5f8c\u5fc3\u5ba4\u983b\u62cd\u306e 1<\/span>\u4f8b\uff0e<\/p>\n

    3\uff09\u4e2d\u8c37\u6d0b\u4ecb, <\/span>\u6b66 \u5bdb, <\/span>\u7027\u6fa4\u826f\u54c9, <\/span>\u5409\u6751\u771f\u543e, <\/span>\u6728\u6751\u5149\u8f1d, <\/span>\u539f\u53e3\u88d5\u7f8e\u5b50, <\/span>\u4f50\u3005\u6728\u5065\u4eba, <\/span>\u5f8c\u85e4\u8ca2\u58eb, <\/span>\u4e09\u6a39\u7950\u5b50, <\/span>\u7d48\u91ce\u5065\u4e00, <\/span>\u4e2d\u6751\u7d18\u898f, <\/span>\u5185\u85e4\u6ecb\u4eba<\/p>\n

    \u5de6\u4e0a\u5927\u9759\u8108\u907a\u6b8b\u306b\u201dleft-sided variant of right top pulmonary vein\u201d<\/span>\u3092\u5408\u4f75\u3057\u305f\u5fc3\u623f\u7d30\u52d5\u306e1<\/span>\u4f8b. <\/span>\u65e5\u672c\u4e0d\u6574\u8108\u5fc3\u96fb\u5b66\u4f1a\u2002<\/span>\u30ab\u30c6\u30fc\u30c6\u30eb\u30a2\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\u95a2\u9023\u79cb\u5b63\u5927\u4f1a2023, <\/span>\u798f\u5ca1, 2023.11.18<\/span><\/p>\n

    \u7b2c69<\/span>\u56de\u65e5\u672c\u4e0d\u6574\u8108\u5fc3\u96fb\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30002023.7.6-9<\/span>\uff08\u672d\u5e4c\uff09<\/h4>\n

    1\uff09\u91d1\u53e4\u5584\u660e<\/p>\n

    \u6559\u80b2\u8b1b\u6f14\uff14\uff1aEPS<\/span>\u306b\u5fc5\u8981\u306a\u57fa\u790e\u77e5\u8b58\uff08\u4e0a\u8cea\u983b\u62cd\u7de8\u3001\u5fc3\u5ba4\u983b\u62cd\u7de8\uff09<\/p>\n

    \u7b2c270\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u95a2\u6771\u7532\u4fe1\u8d8a\u5730\u65b9\u4f1a\u30002023.12.16<\/span>\uff08\u6771\u4eac\uff09<\/h4>\n

    \u5c0f\u677f\u6a4b\u7d00\u901a<\/p>\n

    \u91cd\u75c7\u5fc3\u4e0d\u5168\u306e\u85ac\u7269\u7642\u6cd5\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8<\/p>\n<\/section>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    \u7b2c35\u56de\u81e8\u5e8a\u4e0d\u6574\u8108\u7814\u7a76\u4f1a\u30002023.1.7\uff08\u6771\u4eac\uff09 \u3010\u512a\u79c0\u6f14\u984c\u8cde\u3011\u5c0f\u91dd\u5c2d\u53f8\u3001\u91d1\u53e4\u5584\u660e\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u9577\u8c37\u5ddd\u3000\u5bdb\u3001\u77f3\u4e95\u79c0\u6a39\uff0e \u4e2d\u4f4d\u51a0\u9759\u8108\u6d1e\u3042\u308b\u3044\u306f\u30d2\u30b9\u675f\u3092\u5fc3\u623f\u6700\u65e9\u671f\u3068\u3059\u308bfast-slow AVNRT\u306e\u4e00\u4f8b\uff0e \u7b2c3\u56de\u65e5\u672c\u4e0d\u6574 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":872,"menu_order":37,"comment_status":"closed","ping_status":"closed","template":"tpl_results.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-874","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=874"}],"version-history":[{"count":8,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/874\/revisions"}],"predecessor-version":[{"id":887,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/874\/revisions\/887"}],"up":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/872"}],"wp:attachment":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}